1. Home
  2. ENTA vs TGEN Comparison

ENTA vs TGEN Comparison

Compare ENTA & TGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • TGEN
  • Stock Information
  • Founded
  • ENTA 1995
  • TGEN 2000
  • Country
  • ENTA United States
  • TGEN United States
  • Employees
  • ENTA N/A
  • TGEN N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • TGEN
  • Sector
  • ENTA Health Care
  • TGEN
  • Exchange
  • ENTA Nasdaq
  • TGEN NYSE
  • Market Cap
  • ENTA 160.3M
  • TGEN 146.1M
  • IPO Year
  • ENTA 2013
  • TGEN N/A
  • Fundamental
  • Price
  • ENTA $7.28
  • TGEN $6.21
  • Analyst Decision
  • ENTA Buy
  • TGEN
  • Analyst Count
  • ENTA 4
  • TGEN 0
  • Target Price
  • ENTA $18.00
  • TGEN N/A
  • AVG Volume (30 Days)
  • ENTA 168.6K
  • TGEN 389.3K
  • Earning Date
  • ENTA 08-04-2025
  • TGEN 08-11-2025
  • Dividend Yield
  • ENTA N/A
  • TGEN N/A
  • EPS Growth
  • ENTA N/A
  • TGEN N/A
  • EPS
  • ENTA N/A
  • TGEN N/A
  • Revenue
  • ENTA $64,462,999.00
  • TGEN $23,711,209.00
  • Revenue This Year
  • ENTA N/A
  • TGEN $155.81
  • Revenue Next Year
  • ENTA $0.48
  • TGEN $19.42
  • P/E Ratio
  • ENTA N/A
  • TGEN N/A
  • Revenue Growth
  • ENTA N/A
  • TGEN N/A
  • 52 Week Low
  • ENTA $4.09
  • TGEN $0.65
  • 52 Week High
  • ENTA $17.24
  • TGEN $6.42
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 60.14
  • TGEN N/A
  • Support Level
  • ENTA $6.87
  • TGEN N/A
  • Resistance Level
  • ENTA $8.47
  • TGEN N/A
  • Average True Range (ATR)
  • ENTA 0.50
  • TGEN 0.00
  • MACD
  • ENTA -0.03
  • TGEN 0.00
  • Stochastic Oscillator
  • ENTA 54.44
  • TGEN 0.00

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About TGEN TECOGEN INC

Tecogen Inc, designs, manufactures, markets, and maintains high-efficiency, ultra-clean cogeneration products. It operates in three business segments, namely Products, Services, and Energy Production. Products segment designs, manufactures, and sells industrial and commercial cogeneration systems. The services segment provides operations and maintenance services and turn-key installation for products under long-term service contracts. The Energy Production segment sells energy in the form of electricity, heat, hot water, and cooling to the customers under long-term energy sales agreements.

Share on Social Networks: